Agilent Technologies, Inc. (NYSE:A) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

Several other analysts have also commented on A. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a report on Tuesday, May 16th. Deutsche Bank AG raised their price objective on shares of Agilent Technologies from $58.00 to $62.00 and gave the stock a “buy” rating in a report on Monday, May 22nd. Cowen and Company raised their price objective on shares of Agilent Technologies from $53.00 to $62.00 and gave the stock a “market perform” rating in a report on Tuesday, May 23rd. Jefferies Group LLC raised their price objective on shares of Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Finally, Robert W. Baird raised their price objective on shares of Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, May 24th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $60.12.

Shares of Agilent Technologies (NYSE:A) opened at 59.33 on Friday. The firm has a market capitalization of $19.06 billion, a PE ratio of 33.35 and a beta of 1.30. Agilent Technologies has a 52-week low of $42.92 and a 52-week high of $61.84. The stock has a 50 day moving average price of $60.10 and a 200-day moving average price of $55.69.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, May 22nd. The medical research company reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.10. Agilent Technologies had a net margin of 13.41% and a return on equity of 16.49%. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the business posted $0.44 earnings per share. Agilent Technologies’s quarterly revenue was up 8.1% compared to the same quarter last year. Equities analysts forecast that Agilent Technologies will post $2.23 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/agilent-technologies-inc-a-lowered-to-buy-at-bidaskclub/1476320.html.

In related news, insider Patrick Kaltenbach sold 2,074 shares of the firm’s stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $60.43, for a total transaction of $125,331.82. Following the completion of the sale, the insider now owns 42,212 shares of the company’s stock, valued at $2,550,871.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Didier Hirsch sold 5,710 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $60.60, for a total transaction of $346,026.00. The disclosure for this sale can be found here. Insiders have sold 112,608 shares of company stock valued at $6,737,509 in the last three months.

Large investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue bought a new stake in Agilent Technologies during the first quarter worth approximately $384,000. Columbus Circle Investors increased its stake in Agilent Technologies by 3.8% in the first quarter. Columbus Circle Investors now owns 127,210 shares of the medical research company’s stock worth $6,726,000 after buying an additional 4,643 shares during the period. Boston Advisors LLC increased its stake in Agilent Technologies by 27.7% in the first quarter. Boston Advisors LLC now owns 40,302 shares of the medical research company’s stock worth $2,131,000 after buying an additional 8,730 shares during the period. Coastline Trust Co bought a new stake in Agilent Technologies during the first quarter worth approximately $277,000. Finally, DnB Asset Management AS increased its stake in Agilent Technologies by 14.1% in the first quarter. DnB Asset Management AS now owns 40,449 shares of the medical research company’s stock worth $2,139,000 after buying an additional 5,000 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.